Life Sciences

Overview


Chambers USA 2018, Client Quote

Whether you’re a cutting-edge medical device startup or a global biopharma leader, it’s mission that drives you. Amid pricing and payor pressures, regulatory scrutiny, emerging innovations and challenging pipelines, market demand continues to grow. To broaden your field of vision as you navigate this dynamic industry, you need integrated, global counsel that can help clear your path to success.

Show More

Results


  • Eli Lilly and Company (NYSE: LLY) with multiple transactions, including the acquisitions of Pacific Biotech Inc. for $135 million and Devices for Vascular Intervention Inc. for $120 million
  • TOLMAR Inc., with a complete defense victory, in an ANDA case in the US District Court for the District of Delaware, where TOLMAR was first to file an ANDA for a generic calcipotriene cream product for the treatment of psoriasis and as a result of the process the plaintiff voluntarily dismissed its case allowing TOLMAR to immediately bring to market its generic product.
  • Amgen Inc., the world’s largest biotech company, with securing a motion to dismiss before the US Court of Appeals for the Third Circuit in a high stakes, class action antitrust case brought by Warren General Hospital, alleging that Amgen had illegally tied sales of its blockbuster drugs, Neulasta® and Neupogen®, with another of its drugs

Show More

People


McDermott’s Life Sciences Team will get you closer to your goals. Composed of top lawyers with demonstrated strength across intellectual property, regulatory, transactional and litigation law, we’re a purpose-built team of thought leaders united by a passion for our work.

Life Sciences

Insights & Events / Media

April 30, 2017

Re-Introduction of the Prohibition of Online Sales of Rx-Drugs – Admissible Under Constitutional ...

March 2017

April 30, 2015

Comparable Drugs in Price Negotiations Under Sec. 130b SGB V

March 2015

CMS Issues Guidance on Policy and Payment Issues Affected by Introduction of ...

April 1, 2014

How Changes To 'Dear Doctor Letters' Will Impact Industry

February 26, 2014

Generic Drug and API Producers Deal with the Bolar Exemption

February 19, 2014

Yet another Health Reform and Seizure of Retiring Doctors' Practices

January 2014

Patent Expirations: Generic Drugs and Active Ingredient Producers from the Perspective of ...

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

... 33